Setmelanotide
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
Rhythm · Phase 2 · Completed · Enrollment 74
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Setmelanotide | 9.1% | n/r | n/r | n/r |
| Placebo | 5.6% | n/r | n/r | n/r |
Not shown
Every selected arm is drawn.